カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の医薬品原薬（API）市場：種類別（革新的、ジェネリック）、メーカー別、合成別、製品別、薬物別、用途別

◆英語タイトル：Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027
	◆商品コード：PH1262-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2022年12月15日 ◆ページ数：361 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

マーケッツアンドマーケッツ社は、世界の医薬品原薬（API）市場規模が2022年1459億ドルから2027年2164億ドルに達し、予測期間中に年平均8.2％で成長すると予測しています。本調査報告書では、医薬品原薬（API）の世界市場を調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（革新的、ジェネリック）分析、効力別（従来型、高活性医薬品成分）分析、合成別（合成、バイオテクノロジー）分析、薬物別（市販薬、処方薬）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、企業情報などの情報を整理しています。なお、当資料には、Pfizer,Inc. (US)、Novartis AG (Switzerland)、Sanofi (France)、Boehringer Ingelheim (Germany)、Bristol-Myers Squibb (US)、Teva Pharmaceutical Industries Ltd. (Israel)、Eli Lilly and Company (US)、GlaxoSmithKline plc (UK)、Merck & Co.,Inc. (US)、F. Hoffmann-La Roche Ltd. (Switzerland)などの企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の医薬品原薬（API）市場規模：種類別
- 革新的APIの市場規模
- ジェネリックAPIの市場規模
・世界の医薬品原薬（API）市場規模：効力別
- 従来型医薬品成分の市場規模
- 高活性医薬品成分の市場規模
・世界の医薬品原薬（API）市場規模：合成別
- 合成APIの市場規模
- バイオテクノロジーAPIの市場規模
・世界の医薬品原薬（API）市場規模：薬物別
- 市販薬の市場規模
- 処方薬の市場規模
・世界の医薬品原薬（API）市場規模：地域別
- 北米の医薬品原薬（API）市場規模
- ヨーロッパの医薬品原薬（API）市場規模
- アジア太平洋の医薬品原薬（API）市場規模
- その他地域の医薬品原薬（API）市場規模
・競争状況
・企業情報

“世界の医薬品原薬（API）市場は、予測期間中の年平均成長率8.2%で、2022年までに1,459億米ドルに達し、2027年には2,164億米ドルに達すると推定”
バイオ医薬品の取り込みの増加、ジェネリック医薬品の重要性の高まり、精密医療への注目の高まりなどの要因が、世界の医薬品原薬（API）市場の成長を促進する主な要因となっています。

“バイオ医薬品原薬（API）セグメントは予測期間中に最も高いCAGRで成長する見込み”
合成の種類に基づいて、API市場は合成APIとバイオテクノロジーAPIに分類されます。2021年には、合成APIセグメントが最大のシェアを占めました。しかし、バイオAPI分野は予測期間中、より高い成長率が見込まれています。作用の特異性によるバイオ医薬品への需要の高まりやバイオテクノロジーの進歩などの要因が、市場の成長を促進しています。

“モノクローナル抗体分野が世界のバイオ医薬品原薬（API）市場で最大のシェアを占める見込み”
製品別に見ると、バイオ医薬品原薬（API）市場は、モノクローナル抗体、ホルモン・成長因子、サイトカイン、融合タンパク質、治療用酵素、組み換えワクチン、血液因子に区分されます。2021年には、モノクローナル抗体分野がバイオ医薬品原薬（API）市場で最大のシェアを占めると推定されます。

“予測期間中、北米が市場を占める”
2021年、北米が市場を占め、次いで欧州が占めました。この地域のAPI市場全体の成長を促進する主な要因には、主要な製薬・バイオ医薬品製造施設の存在、ジェネリック医薬品に対する政府の関心の高まり、生物製剤や特殊医薬品の需要の高まり、APIの製造工程における技術進歩などがあります。この市場セグメントは、経済・医療危機対策やブランド薬の低価格・ジェネリック医薬品の導入が相まって、緩やかな成長が見込まれています。

主要参入企業のプロフィール内訳
– 企業タイプ別ティア1：37%、ティア2：22%、ティア3：41％
– 役職別 Cレベル：25%、取締役：20%、その他：55％
– 地域別北米：40%、ヨーロッパ：27%、アジア太平洋地域：20%、その他の地域：13％

レポート掲載企業一覧
• Pfizer, Inc. (US),
• Novartis AG (Switzerland),
• Sanofi (France),
• Boehringer Ingelheim (Germany),
• Bristol-Myers Squibb (US),
• Teva Pharmaceutical Industries Ltd. (Israel),
• Eli Lilly and Company (US),
• GlaxoSmithKline plc (UK),
• Merck & Co., Inc. (US),
• AbbVie Inc. (US),
• F. Hoffmann-La Roche Ltd. (Switzerland),
• AstraZeneca (UK),
• Cipla, Inc. (India),
• Mylan N.V. (US),
• Dr. Reddy’s Laboratories Ltd. (India),
• Sun Pharmaceutical Industries Ltd. (India),
• API Pharma Tech (India),
• BDR Pharmaceuticals Internationals Pvt. Ltd. (India),
• Sreepathi Pharmaceuticals Limited (India),
• Shilpa Medicare Limited (India),
• Evonik Industries AG (Germany),
• Aurobindo Pharma Limited (India).

調査範囲
本レポートは世界のAPI市場の全体像を提供します。タイプ、力価、合成のタイプ、医薬品のタイプ、治療用途、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。さらに、主要市場プレイヤーの企業プロフィール、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、API市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、本レポートは、利害関係者が競争状況をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。また、利害関係者が市場の動向を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供することも可能になります。

❖ レポートの目次 ❖

1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.2.1 INCLUSIONS AND EXCLUSIONS 48
1.3 MARKET SCOPE 49
1.3.1 MARKETS COVERED 49
FIGURE 1 MARKET SEGMENTATION 49
1.3.2 GEOGRAPHIC SCOPE 49
1.3.3 YEARS CONSIDERED 50
1.4 CURRENCY 50
1.5 LIMITATIONS 50
1.6 STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
FIGURE 2 RESEARCH DESIGN 52
2.1.1 SECONDARY DATA 53
2.1.1.1 Key data from secondary sources 53
2.1.2 PRIMARY DATA 54
2.1.2.1 Primary sources 54
2.1.2.2 Key data from primary sources 55
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 55
2.2 MARKET SIZE ESTIMATION 56
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 56
FIGURE 5 MARKET SIZE ESTIMATION: DEMAND-SIDE ANALYSIS 56
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 58
FIGURE 6 DATA TRIANGULATION METHODOLOGY 58
2.4 MARKET SHARE ESTIMATION 59
2.5 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2022 VS. 2027 (USD BILLION) 60
FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY TYPE OF SYNTHESIS, 2021 61
FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2022 VS. 2027 (USD BILLION) 61
FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2022 VS. 2027 (USD BILLION) 62
FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY THERAPEUTIC APPLICATION, 2021 62
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 63
4 PREMIUM INSIGHTS 65
4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW 65
FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 65
4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE AND COUNTRY (2021) 66
FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 66
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH IN FORECAST PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 DRIVERS 68
5.2.1.1 Pharmaceutical and biopharmaceutical capacity expansion 68
5.2.1.2 Growing importance of generics 69
TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2021 70
5.2.1.3 Increasing uptake of biopharmaceuticals 70
TABLE 2 US: INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN 2021 71
5.2.1.4 Technological advancements in API manufacturing 71
5.2.1.5 Focus on precision medicine 72
5.2.1.6 Increasing incidence of chronic diseases 73
5.2.2 RESTRAINTS 74
5.2.2.1 Complications during API manufacturing 74
5.2.2.2 Low profit margins and high manufacturing costs 74
5.2.3 OPPORTUNITIES 74
5.2.3.1 Emerging biosimilars market 74
TABLE 3 US: INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL (2021–2022) 75
5.2.3.2 Highly potent active pharmaceutical ingredients 75
5.2.3.3 Emerging markets 75
5.2.3.4 Emerging technologies/processes 76
5.2.4 CHALLENGES 76
5.2.4.1 Increasing penetration of counterfeit drugs 76
5.3 VALUE CHAIN ANALYSIS 77
FIGURE 17 MAJOR VALUE ADDED DURING MANUFACTURING 77
5.4 SUPPLY CHAIN ANALYSIS 78
FIGURE 18 DIRECT DISTRIBUTION—STRATEGY PREFERRED BY PROMINENT COMPANIES 78
5.5 ECOSYSTEM ANALYSIS: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 79
FIGURE 19 ECOSYSTEM ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 79
5.6 PATENT ANALYSIS 80
FIGURE 20 PATENT APPLICATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS, JANUARY 2010–DECEMBER 2021 80
5.7 KEY CONFERENCES AND EVENTS 81
TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–2023 81
5.8 TARIFF AND REGULATORY LANDSCAPE 82
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.9 PORTER’S FIVE FORCES ANALYSIS 83
TABLE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
5.9.1 THREAT OF NEW ENTRANTS 83
5.9.2 THREAT OF SUBSTITUTES 83
5.9.3 BARGAINING POWER OF SUPPLIERS 83
5.9.4 BARGAINING POWER OF BUYERS 83
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 84
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 84
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS 84
5.10.2 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS 84
FIGURE 22 KEY BUYING CRITERIA FOR END USERS 84
5.11 PRICING ANALYSIS 85
TABLE 9 IMPORTERS FOR ANTIBIOTICS (HS CODE – 2941) 85
TABLE 10 EXPORTERS FOR ANTIBIOTICS (HS CODE – 2941) 86
TABLE 11 IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934) 87
TABLE 12 EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934) 88
TABLE 13 IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937) 89
TABLE 14 EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937) 90
5.12 TRADE ANALYSIS 91
TABLE 15 TOP 10 IMPORTERS FOR ANTIBIOTICS (HS CODE – 2941) 91
TABLE 16 TOP 10 EXPORTERS OF ANTIBIOTICS (HS CODE – 2941) 91
TABLE 17 TOP 10 IMPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934) 92
TABLE 18 TOP 10 EXPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE – 2934) 92
TABLE 19 TOP 10 IMPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937) 93
TABLE 20 TOP 10 EXPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE – 2937) 93
6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 94
6.1 INTRODUCTION 95
TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION) 95
6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT) 95
TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2020–2027 (USD BILLION) 95
TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION) 96
6.3 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 96
6.3.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET 96
TABLE 24 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 97
TABLE 25 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 97
TABLE 26 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 98
TABLE 27 ASIA PACIFIC: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 98
TABLE 28 REST OF THE WORLD: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 99
6.4 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 99
6.4.1 GOVERNMENT INITIATIVES SUPPORTING ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH 99
TABLE 29 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 99
TABLE 30 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 100
TABLE 31 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 100
TABLE 32 ASIA PACIFIC: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 101
TABLE 33 REST OF THE WORLD: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 101
7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 102
7.1 INTRODUCTION 103
TABLE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION) 103
7.2 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS 103
7.2.1 APPLICATION IN VARIOUS THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH 103
TABLE 35 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 104
TABLE 36 NORTH AMERICA: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 104
TABLE 37 EUROPE: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 104
TABLE 38 ASIA PACIFIC: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 105
TABLE 39 REST OF THE WORLD: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 105
7.3 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 105
7.3.1 INCREASING APPLICATION ACROSS RANGE OF THERAPEUTIC AREAS TO DRIVE MARKET 105
TABLE 40 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 106
TABLE 41 NORTH AMERICA: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 106
TABLE 42 EUROPE: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 107
TABLE 43 ASIA PACIFIC: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 107
TABLE 44 REST OF THE WORLD: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 108
8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 109
8.1 INTRODUCTION 110
TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION) 110

8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS
(CAPTIVE AND MERCHANT) 110
TABLE 46 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2020–2027 (USD BILLION) 110
TABLE 47 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION) 111
8.3 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 111
TABLE 48 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 112
TABLE 49 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 112
TABLE 50 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 113
TABLE 51 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 113
TABLE 52 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 114
8.3.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 114
TABLE 53 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION) 114
8.3.1.1 Innovative synthetic APIs 115
8.3.1.1.1 High value of innovative APIs to drive market 115
TABLE 54 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 115
TABLE 55 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 115
TABLE 56 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 116
TABLE 57 ASIA PACIFIC: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 116
TABLE 58 REST OF THE WORLD: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 117
8.3.1.2 Generic synthetic APIs 117
8.3.1.2.1 Initiatives to promote penetration of generics to support market growth 117
TABLE 59 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 118
TABLE 60 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 118
TABLE 61 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 119
TABLE 62 ASIA PACIFIC: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 119
TABLE 63 REST OF THE WORLD: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 120
8.4 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 120
TABLE 64 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 121
TABLE 65 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 121
TABLE 66 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 122
TABLE 67 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 122
TABLE 68 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 123
8.4.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 123
TABLE 69 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION) 123
8.4.1.1 Innovative biotech APIs 123
8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market 123
TABLE 70 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 124
TABLE 71 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 124
TABLE 72 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 125
TABLE 73 ASIA PACIFIC: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 125
TABLE 74 REST OF THE WORLD: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 126
8.4.1.2 Generic biotech APIs 126
8.4.1.2.1 Increasing demand for biosimilar drugs due to cost-effectiveness to drive market 126
TABLE 75 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION) 127
TABLE 76 NORTH AMERICA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 127
TABLE 77 EUROPE: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 128
TABLE 78 ASIA PACIFIC: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 128
TABLE 79 REST OF THE WORLD: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 129
8.4.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 129
TABLE 80 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION) 129
8.4.2.1 Monoclonal antibodies 130
8.4.2.1.1 Growing applications of antibody-drug conjugates in treatment of cancer to drive growth 130
TABLE 81 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2020–2027 (USD BILLION) 130
TABLE 82 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION) 131
TABLE 83 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION) 131
TABLE 84 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION) 132
TABLE 85 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020–2027 (USD BILLION) 132
8.4.2.2 Hormones and growth factors 132
8.4.2.2.1 Growing incidence of hormonal disorders to drive market 132
TABLE 86 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY REGION, 2020–2027 (USD BILLION) 133
TABLE 87 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 133
TABLE 88 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 134
TABLE 89 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 134
TABLE 90 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 135
8.4.2.3 Cytokines 135
8.4.2.3.1 Interferons and interleukins boost immune system 135
TABLE 91 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2020–2027 (USD BILLION) 135
TABLE 92 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION) 136
TABLE 93 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION) 136
TABLE 94 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION) 137
TABLE 95 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020–2027 (USD BILLION) 137
8.4.2.4 Fusion proteins 137
8.4.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive market 137
TABLE 96 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2020–2027 (USD BILLION) 138
TABLE 97 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION) 138
TABLE 98 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION) 139
TABLE 99 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION) 139
TABLE 100 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020–2027 (USD BILLION) 140
8.4.2.5 Recombinant vaccines 140
8.4.2.5.1 Growing prevalence of infectious diseases to boost vaccine development 140
TABLE 101 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2020–2027 (USD BILLION) 140
TABLE 102 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION) 141
TABLE 103 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION) 141
TABLE 104 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION) 142
TABLE 105 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020–2027 (USD BILLION) 142
8.4.2.6 Therapeutic enzymes 142
8.4.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive market 142
TABLE 106 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2020–2027 (USD BILLION) 143
TABLE 107 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020–2027 (USD BILLION) 143
TABLE 108 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020–2027 (USD BILLION) 144
TABLE 109 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020–2027 (USD BILLION) 144
TABLE 110 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, 2020–2027 (USD BILLION) 145
8.4.2.7 Blood factors 145
8.4.2.7.1 Growing incidence of hemophilia to drive market 145
TABLE 111 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2020–2027 (USD BILLION) 145
TABLE 112 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 146
TABLE 113 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 146
TABLE 114 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020–2027 (USD BILLION) 147
TABLE 115 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, 2020–2027 (USD BILLION) 147
8.4.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 148
TABLE 116 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION) 148
8.4.3.1 Mammalian expression systems 148
8.4.3.1.1 Ability to carry post-translational modifications to drive adoption 148
TABLE 117 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION) 149
TABLE 118 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 149
TABLE 119 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 150
TABLE 120 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 150
TABLE 121 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 151
8.4.3.2 Microbial expression systems 151
8.4.3.2.1 High expression levels of proteins at low costs to drive market 151
TABLE 122 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION) 151
TABLE 123 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 152
TABLE 124 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 152
TABLE 125 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 153
TABLE 126 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 153
8.4.3.3 Yeast expression systems 153
8.4.3.3.1 Efficient protein secretion, simple purification, and endotoxin-free products to boost demand 153
TABLE 127 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION) 154
TABLE 128 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 154
TABLE 129 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 155
TABLE 130 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 155
TABLE 131 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 156
8.4.3.4 Insect expression systems 156
8.4.3.4.1 Efficient post-translational modifications to boost adoption 156
TABLE 132 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION) 156
TABLE 133 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 157
TABLE 134 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 157
TABLE 135 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 158
TABLE 136 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 158
8.4.3.5 Other expression systems 158
TABLE 137 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2020–2027 (USD BILLION) 159
TABLE 138 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 159
TABLE 139 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 160
TABLE 140 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 160
TABLE 141 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020–2027 (USD BILLION) 161
9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 162
9.1 INTRODUCTION 163
TABLE 142 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION) 163
9.2 PRESCRIPTION DRUGS 163
9.2.1 GROWING DISEASE PREVALENCE TO SUPPORT MARKET GROWTH 163
TABLE 143 PRESCRIPTION DRUGS MARKET, BY REGION, 2020–2027 (USD BILLION) 164
TABLE 144 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 164
TABLE 145 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 165
TABLE 146 ASIA PACIFIC: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 165
TABLE 147 REST OF THE WORLD: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 166
9.3 OVER-THE-COUNTER DRUGS 166
9.3.1 INCREASED SALES OF OTC DRUGS DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS 166
TABLE 148 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2020–2027 (USD BILLION) 167
TABLE 149 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 167
TABLE 150 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 168
TABLE 151 ASIA PACIFIC: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 168
TABLE 152 REST OF THE WORLD: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020–2027 (USD BILLION) 169
10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION 170
10.1 INTRODUCTION 171
TABLE 153 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION) 171
10.2 COMMUNICABLE DISEASES 171
10.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT 171
TABLE 154 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2020–2027 (USD BILLION) 172
TABLE 155 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 172
TABLE 156 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 173
TABLE 157 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 173
TABLE 158 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 174
10.3 ONCOLOGY 174
10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT MARKET GROWTH 174
TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD BILLION) 174
TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION) 175
TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION) 175
TABLE 162 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION) 176
TABLE 163 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD BILLION) 176
10.4 DIABETES 177
10.4.1 HIGH PREVALENCE OF DIABETES TO DRIVE MARKET 177
TABLE 164 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2020–2027 (USD BILLION) 177
TABLE 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION) 177
TABLE 166 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION) 178
TABLE 167 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION) 178
TABLE 168 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD BILLION) 179
10.5 CARDIOVASCULAR DISEASES 179
10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES 179
TABLE 169 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD BILLION) 179
TABLE 170 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 180
TABLE 171 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 180
TABLE 172 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 181
TABLE 173 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 181
10.6 PAIN MANAGEMENT 182
10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO PROPEL MARKET 182
TABLE 174 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2020–2027 (USD BILLION) 182
TABLE 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION) 182
TABLE 176 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION) 183
TABLE 177 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION) 183
TABLE 178 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020–2027 (USD BILLION) 184
10.7 RESPIRATORY DISEASES 184
10.7.1 HIGH PREVALENCE OF RESPIRATORY DISEASES TO SUPPORT MARKET GROWTH 184
TABLE 179 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020–2027 (USD BILLION) 184
TABLE 180 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 185
TABLE 181 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 185
TABLE 182 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 186
TABLE 183 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020–2027 (USD BILLION) 186
10.8 OTHER THERAPEUTIC APPLICATIONS 186
TABLE 184 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD BILLION) 187
TABLE 185 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION) 187
TABLE 186 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION) 188
TABLE 187 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION) 188
TABLE 188 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD BILLION) 189

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION (Page No. - 190)
11.1 INTRODUCTION
TABLE 189 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020–2027 (USD BILLION)
11.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
TABLE 190 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 191 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 192 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 USD BILLION)
TABLE 193 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 194 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 195 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 196 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 197 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 198 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 199 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.2.1 US
11.2.1.1 Largest market for active pharmaceutical ingredients
TABLE 200 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 201 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 202 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 203 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 204 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 205 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 206 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 207 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 208 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.2.2 CANADA
11.2.2.1 Growing pharmaceutical manufacturing to support market growth
TABLE 209 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 210 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 211 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 212 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 213 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 214 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 215 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 216 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 217 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3 EUROPE
TABLE 218 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 219 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 220 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 221 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 222 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 223 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 224 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 226 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 227 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.1 GERMANY
11.3.1.1 Leading country in terms of infrastructure and competency for R&D
TABLE 228 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 229 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 230 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 231 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 232 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 233 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 234 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 235 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 236 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.2 FRANCE
11.3.2.1 Healthy pharmaceutical production to support API demand
TABLE 237 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 238 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 239 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 240 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 241 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 242 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 243 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 244 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 245 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.3 UK
11.3.3.1 Rising government investments to drive market
TABLE 246 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 247 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 248 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 249 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 250 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 251 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 252 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 253 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 254 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.4 ITALY
11.3.4.1 Growing investment in API production to support market growth
TABLE 255 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 256 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 257 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 259 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 260 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 261 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 262 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 263 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.5 SPAIN
11.3.5.1 Increase in generic drug manufacturing capacity to propel demand for APIs
TABLE 264 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 265 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 266 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 267 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 268 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 269 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 270 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 271 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 272 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.6 HUNGARY
11.3.6.1 Rising incidence of chronic diseases to propel market growth
TABLE 273 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 274 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 275 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 276 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 277 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 278 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 279 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 280 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 281 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.3.7 REST OF EUROPE
TABLE 282 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 283 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 284 REST OF EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 285 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 286 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 287 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 288 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 289 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 290 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
TABLE 291 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 292 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 293 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 294 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 295 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 296 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 297 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 298 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 299 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 300 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.4.1 JAPAN
11.4.1.1 Presence of large pharmaceutical companies to propel market
TABLE 301 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 302 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 303 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 304 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 305 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 306 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 307 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 308 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 309 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.4.2 CHINA
11.4.2.1 Government policies to increase medicine access and affordability to support market growth
TABLE 310 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 311 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 312 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 313 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 314 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 315 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 316 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 317 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 318 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.4.3 INDIA
11.4.3.1 Leading producer of generics
TABLE 319 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 320 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 321 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 322 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 323 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 324 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 325 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 326 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 327 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.4.4 SOUTH KOREA
11.4.4.1 Rising annual drug exports to drive market
TABLE 328 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 329 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 330 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 331 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 332 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 333 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 334 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 335 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 336 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 337 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 338 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 340 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 341 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 342 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 343 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 344 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 345 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.5 REST OF THE WORLD
TABLE 346 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 347 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 348 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 349 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 350 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 351 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 352 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 353 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 354 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 355 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.5.1 ISRAEL
11.5.1.1 Financial support by government to drive market
TABLE 356 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 357 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 358 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 359 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 360 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 361 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 362 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 363 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 364 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)
11.5.2 OTHER COUNTRIES
TABLE 365 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 366 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020–2027 (USD BILLION)
TABLE 367 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 368 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020–2027 (USD BILLION)
TABLE 369 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 370 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020–2027 (USD BILLION)
TABLE 371 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020–2027 (USD BILLION)
TABLE 372 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020–2027 (USD BILLION)
TABLE 373 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD BILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 276)
12.1 OVERVIEW
12.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 25 KEY DEVELOPMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019–2022
12.3 MARKET SHARE ANALYSIS
FIGURE 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
TABLE 374 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEGREE OF COMPETITION
12.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019–2021
12.5 COMPANY EVALUATION QUADRANT
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 28 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION QUADRANT, 2021
12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 29 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021
12.7 REGIONAL FOOTPRINT OF COMPANIES
TABLE 375 REGIONAL FOOTPRINT OF COMPANIES IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2021)
12.8 COMPETITIVE SCENARIO
TABLE 376 KEY PRODUCT LAUNCHES
TABLE 377 KEY DEALS
TABLE 378 OTHER KEY DEVELOPMENTS

13 COMPANY PROFILES (Page No. - 288)
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 PFIZER INC.
TABLE 379 PFIZER INC.: COMPANY OVERVIEW
FIGURE 30 PFIZER, INC.: COMPANY SNAPSHOT (2021)
13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 380 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
FIGURE 31 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
13.1.3 DIVI’S LABORATORIES LIMITED
TABLE 381 DIVI’S LABORATORIES LIMITED: COMPANY OVERVIEW
FIGURE 32 DIVI’S LABORATORIES LIMITED: COMPANY SNAPSHOT (2021)
13.1.4 VIATRIS INC.
TABLE 382 VIATRIS INC.: COMPANY OVERVIEW
FIGURE 33 VIATRIS INC.: COMPANY SNAPSHOT (2021)
13.1.5 NOVARTIS AG
TABLE 383 NOVARTIS AG: COMPANY OVERVIEW
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2021)
13.1.6 SANOFI
TABLE 384 SANOFI: COMPANY OVERVIEW
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2021)
13.1.7 BOEHRINGER INGELHEIM
TABLE 385 BOEHRINGER INGELHEIM: COMPANY OVERVIEW
FIGURE 36 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2021)
13.1.8 BRISTOL-MYERS SQUIBB
TABLE 386 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
FIGURE 37 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2021)
13.1.9 ELI LILLY AND COMPANY
TABLE 387 ELI LILLY AND COMPANY: COMPANY OVERVIEW
FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.10 GLAXOSMITHKLINE PLC
TABLE 388 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
FIGURE 39 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2021)
13.1.11 MERCK & CO., INC.
TABLE 389 MERCK & CO., INC.: COMPANY OVERVIEW
FIGURE 40 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
13.1.12 ABBVIE INC.
TABLE 390 ABBVIE INC.: COMPANY OVERVIEW
FIGURE 41 ABBVIE INC.: COMPANY SNAPSHOT (2021)
13.1.13 F. HOFFMANN-LA ROCHE LTD.
TABLE 391 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 42 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
13.1.14 ASTRAZENECA
TABLE 392 ASTRAZENECA: COMPANY OVERVIEW
FIGURE 43 ASTRAZENECA: COMPANY SNAPSHOT (2021)
13.1.15 DR. REDDY’S LABORATORIES LTD.
TABLE 393 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW
FIGURE 44 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2021)
13.1.16 SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 394 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
13.1.17 CIPLA INC.
TABLE 395 CIPLA INC.: COMPANY OVERVIEW
FIGURE 46 CIPLA INC.: COMPANY SNAPSHOT (2021)
13.1.18 AUROBINDO PHARMA
TABLE 396 AUROBINDO PHARMA: COMPANY OVERVIEW
FIGURE 47 AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT (2021)
13.1.19 EVONIK INDUSTRIES AG
TABLE 397 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
FIGURE 48 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2021)
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments migh

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の医薬品原薬（API）市場：種類別（革新的、ジェネリック）、メーカー別、合成別、製品別、薬物別、用途別(Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の医薬品原薬（API）市場：種類別（革新的、ジェネリック）、メーカー別、合成別、製品別、薬物別、用途別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp